Key facts
- Notable investors include Korea Investment Partners.
- Status: Privately Held (backing).
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for BioSynetics
- ·The full record, as it builds
Funding rounds
No funding rounds for BioSynetics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About BioSynetics
Operator of a biotechnology research firm intended to develop organic nano-emulsion compounds that provide natural alternatives to narcotic and addictive medicines. The company offers a laboratory-tested, organically derived cannabinol formulation produced through molecular decomposition and nano-emulsification, enabling customers to manage sleep deprivation, pain and anxiety with a non-narcotic, water-soluble solution that increases bioavailability without the risk of physical addiction.
- Sector
- Healthcare
- HQ
- Newport Beach, CA, United States
- Website
- biosynetics.com/
- Ownership
- Privately Held (backing)
BioSynetics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in BioSynetics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on BioSynetics in its N-PORT filings yet. We sweep new filings monthly.